Key Takeaways
- Strong quarter, guidance held: Revenue grew toward the upper end of the guided band while EBITDA margin hit 14.6%, driven by capacity utilization, product mix and operational efficiencies rather than one-off gains.
- Non-ibuprofen is now the growth engine: Non-ibuprofen APIs contributed 43% of pharma revenue, up from 36% a year ago, with 67% YoY growth and management "very near" to its 50/50 diversification target.
- Chemical segment delivered: Improved realizations, higher exports and expanded Ethyl Acetate and Acetic Anhydride capacities supported a strong quarter, with management expecting similar performance to continue.
- FY27 guidance reaffirmed, FY28 previewed: Management stays confident on 15–20% revenue growth with 14–15% EBITDA margin for FY27, and offered an early FY28 view of 15–20% top-line growth with 15–17% EBITDA margin, caveated on the scenario holding.
- What to watch next quarter: Whether paracetamol utilization climbs toward the ~70% FY27 exit target, whether Triacetin regulatory approvals land on schedule, and whether export mix holds near the 25–30% guided band.
Profitability: The Quality of the Beat
- Operational, not opportunistic: Management explicitly denied any Q1 inventory gain, attributing the EBITDA margin improvement to higher capacity utilization, better product mix, operational efficiencies and stronger non-ibuprofen API demand.
- Capacity utilization is the core driver: Most pharma assets are running at 80–95% utilization, apart from paracetamol, and management flagged utilization as the more important contributor to operational performance than price.
- Regulated-market mix helped: The mix toward regulated markets rose in the quarter for other API products, aiding the higher EBITDA margin.
- Sequential gross margin dip explained: The March quarter had a few days of inventory valuation benefit; this quarter input and finished prices both rose, but margin was impacted because some big-customer prices were already locked. Management says those differences are now exhausted.
- Other expenses rose on energy and logistics: Power and logistics costs increased during the quarter, but the major part was passed on to customers and there is no material impact.
Mahajan: "The more EBITDA is primarily due to the internal efficiencies of the company, not primarily through the external factors."
Non-Ibuprofen: The Diversification Engine
- The headline shift: Non-ibuprofen products contributed 43% of pharma revenue in Q1 FY27 versus 36% in Q1 FY26, with revenue growing 67% YoY.
- Broad-based, not single-product: Paracetamol turnover contributed mainly to the increase, with clopidogrel and pantoprazole also contributing; management declined to identify the single largest contributor.
- Volume-led growth: The majority of pharma growth came from volume increase rather than price realization, with capacity utilization of API products increasing including non-ibuprofen segments.
- The 50/50 target is close: Management said the company is "very near" to achieving the mid-to-short-term goal of roughly 50% ibuprofen and 50% non-ibuprofen contribution to pharma.
- FY29 ambition: Non-ibuprofen is expected to contribute around 50–55% of the API segment by FY29, with margins equivalent to ibuprofen margins.
- The model is replicable: Management's stated approach is to replicate the leadership model built in ibuprofen across other products.
Singh: "While ibuprofen remains an important part of our portfolio, our strategic focus is increasingly on building IOL as a diversified and integrated API platform, with multiple products contributing to our growth."
Chemical Segment: Quiet Strength
- Strong quarter on multiple fronts: The chemical business delivered improved realizations, efficient raw material procurement, higher exports and operational efficiencies.
- Capacity expansion contributed: Increased capacities of both Ethyl Acetate and Acetic Anhydride supported the better EBITDA margin in the segment.
- Pricing spike has stabilized: Ethyl acetate and acetic anhydride prices increased substantially in March due to the U.S.-Iran war, but have since stabilized and have not been on an upward trend for the last month.
- Spread outlook steady: Management expects the delta between raw material and ethyl acetate prices to remain constant in upcoming quarters.
- Export mix is multi-factor: Higher export contribution reflects better product mix, operational efficiency, better realization and customer reach, not any single dominant reason.
Paracetamol & New Products
- Paracetamol ramp is on track: Currently operating at ~55% of enhanced capacity, with an expected exit at ~70% by end of FY27.
- Demand is healthy: Management foresees good demand in paracetamol, with traction building in both domestic and export markets.
- Triacetin launched, approvals pending: Production started in May; regulatory approvals are expected in two to three quarters, with capacity increasing slowly as market penetration grows.
- China NMPA approval for clopidogrel: Received during the quarter, further expanding regulatory reach; ibuprofen was already approved in China.
- US FDA pipeline: All products have CEP approval, five products have US FDA approval, and another two to three products are lined up as formulators have filed their ANDAs.
- R&D capability build: The company purchased XRD, LCMS and GCMS machines, high-end analytical equipment to analyze impurity profiles at stringent levels.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY27 revenue growth | 15–20% growth | FY27 |
| FY27 EBITDA margin | 14–15% | FY27 |
| FY27 export contribution | 25–30% of revenue | FY27 |
| Paracetamol utilization | Reach ~70% of enhanced capacity | End of FY27 |
| Non-ibuprofen pharma contribution | Reach ~50% of pharma | Near term |
| FY28 revenue growth | 15–20% top-line growth | FY28, caveated on scenario holding |
| FY28 EBITDA margin | 15–17% | FY28, caveated on scenario holding |
| FY29 non-ibuprofen API contribution | 50–55% of API segment | FY29 |
| Triacetin regulatory approvals | Approvals expected | Two to three quarters |
| Annual capex | ~₹200 Cr per year, 60% expansion/new products, 40% infrastructure | Ongoing, long-term view |
What Management Would Not Say
- No volume/realization split: Management declined to share the exact split of pharma growth between volume and realization, saying "we do not share that detailed information over the call."
- No regulated/non-regulated export bifurcation: An analyst asked how much of the ₹200 Cr non-ibuprofen quarterly revenue comes from regulated versus non-regulated markets; management said they do not have the exact bifurcation.
- No competitor commentary: Asked whether IOL has beaten SMS Pharma on ibuprofen manufacturing technology, management declined to comment on competitors, stating they don't know what others are doing.
- No backward integration specifics: Asked about specific intermediates or KSMs being evaluated, management deflected, saying details will be shared only when proof of concept is ready.
- No CMO update: Asked about CMO space opportunities, management said they will update once a clear proof-of-concept is ready.
- No Triacetin margin comparison: Management declined to discuss EBITDA margin on a product basis, saying the two products cannot be compared because usage is totally different.
- 101-acre land timing vague: Statutory permissions are underway and R&D is working on product mix; work will start once proof-of-concept is ready, "probably not in this FY."
Singh: "We need to be correct when we say something rather than we don't want to caught saying something which is not able to achieve."
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹756 cr, up 37% YoY from ₹551 cr |
| EBITDA | ₹111 cr, up 60.7% YoY from ₹69.5 cr |
| EBITDA margin | 14.6%, up from 12.4% in Q1 FY26 |
| PAT | ₹64.5 cr, up 89.9% YoY from ₹34 cr |
| PAT margin | 8.4%, up from 6.1% in Q1 FY26 |
| Export contribution | 28.5% of revenue, up from 24.4% in Q1 FY26 |
| Non-ibuprofen share of pharma revenue | 43%, up from 36% in Q1 FY26 |
| Non-ibuprofen revenue growth | 67% YoY |
| Pharma revenue growth | 43% YoY |
| Paracetamol capacity utilization | ~55% of enhanced 10,800 MTPA capacity, expected to reach ~70% by end of FY27 |
| Other pharma asset utilization | 80% to 95% capacity utilization |
| FY27 revenue growth guidance | 15% to 20% |
| FY27 EBITDA margin guidance | 14% to 15% |
| FY27 export guidance | 25% to 30% of revenue |
| FY28 revenue growth guidance | 15% to 20% |
| FY28 EBITDA margin guidance | 15% to 17% |
| FY29 non-ibuprofen target | 50% to 55% of API segment |
| Capex guidance | ₹200 cr to ₹250 cr, 60% for expansion and new products, 40% for infrastructure |
| R&D investment in FY26 | ₹26 cr |
| Triacetin revenue potential | ~₹120 cr per year at steady state |
| US FDA approved products | 5 products approved, another 2 to 3 in pipeline via formulators' ANDA filings |